FDA expands use of Merck’s CAPVAXIVE for high-risk children and teens
The expanded approval covers children and teens with chronic conditions that increase vulnerability to pneumococcal infections
The expanded approval covers children and teens with chronic conditions that increase vulnerability to pneumococcal infections
Subscribe To Our Newsletter & Stay Updated